Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript Summary
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript Summary
Total operating expenses, excluding share-based compensation, saw a modest year-over-year increase primarily driven by the progression of the CYPRESS study.The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript:
以下是Theravance Biopharma, Inc. (TBPH) 2024年第三季度業績會實錄摘要:
Financial Performance:
財務表現：
Theravance Biopharma reported YUPELRI quarterly net sales of $62.2 million, marking a 7% growth year-on-year and 14% quarter-on-quarter.
Collaboration revenue for the quarter was $16.9 million, representing an 8% increase compared with last year.
Total operating expenses, excluding share-based compensation, saw a modest year-over-year increase primarily driven by the progression of the CYPRESS study.
The company expects to receive a $50 million sales milestone in 2024 from GSK for Trelegy, which showed a quarterly sales of $789 million.
Theravance Biopharma報告YUPELRI季度淨銷售額爲6220萬美元，同比增長7%，環比增長14%。
本季度合作營收爲1690萬美元，較去年同期增長8%。
總營業費用，不包括股權報酬，較去年同比略有增長，主要受CYPRESS研究進展推動。
公司預計從吉利德科學（GSK）處於2024年獲得5000萬美元的銷售里程碑獎勵，Trelegy季度銷售額爲78900萬美元。
Business Progress:
業務進展：
Ongoing pivotal CYPRESS study for Ampreloxetine is on track with updated timelines, expecting significant milestones in 2025.
Formation of a strategic review committee to explore alternatives for enhancing company value, involving key assets like YUPELRI, Ampreloxetine, Trelegy.
Continued strong performance in both the hospital and community sectors for YUPELRI, achieving new market share highs.
Filed an NDA in China for YUPELRI, anticipating significant market opportunity with potential milestones and royalties on approval.
Ampreloxetine進行中的關鍵CYPRESS研究進展順利，更新的時間表符合預期，預計在2025年實現重要里程碑。
成立戰略審查委員會，探討增強公司價值的替代方案，涉及YUPELRI、Ampreloxetine、Trelegy等關鍵資產。
YUPELRI在醫院和社區領域持續強勁表現，取得新的市場份額高點。
在中國爲YUPELRI提交了新藥申請，預計在獲批時有巨大市場機會，可能會有重要的里程碑和特許權。
Opportunities:
機會：
Strong growth in the commercial business driven by YUPELRI, with continued expansion in hospital and community settings expected.
Anticipated receipt of sales milestone from GSK's Trelegy performance presents a significant financial opportunity.
Strategic exploration of company assets including key drugs and tax attributes aimed at enhancing shareholder value.
由YUPELRI推動商業業務強勁增長，在醫院和社區環境中不斷擴張，預計將繼續增長。
預計從GSK的Trelegy表現中獲得銷售里程碑，帶來重要的財務機會。
戰略性探索公司資產，包括關鍵藥物和稅收屬性，旨在增強股東價值。
Risks:
風險：
Potential challenges in achieving future sales targets for Trelegy amid competitive market pressures.
Regulatory hurdles and market entry challenges in China for YUPELRI could impact expected milestones and revenue growth.
在競爭激烈的市場壓力下，實現Trelegy未來銷售目標可能面臨潛在挑戰。
YUPELRI在中國面臨的監管障礙和市場準入挑戰可能會影響預期的里程碑和營業收入增長。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。